ChemicalBook >> journal list >> Advanced Science >>article
Advanced Science

Advanced Science

IF: 14.3
Download PDF

RNF126‐Mediated MRE11 Ubiquitination Activates the DNA Damage Response and Confers Resistance of Triple‐Negative Breast Cancer to Radiotherapy

Published:23 December 2022 DOI: 10.1002/advs.202203884 PMID: 36563124
Wenjing Liu, Min Zheng, Rou Zhang, Qiuyun Jiang, Guangshi Du, Yingying Wu, Chuanyu Yang, Fubing Li, Wei Li, Luzhen Wang, Jiao Wu, Lei Shi, Wenhui Li, Kai Zhang, Zhongmei Zhou, Rong Liu, Yingzheng Gao, Xinwei Huang, Songqing Fan, Xu Zhi, Dewei Jiang, Ceshi Chen

Abstract

Triple-negative breast cancer (TNBC) has higher molecular heterogeneity and metastatic potential and the poorest prognosis. Because of limited therapeutics against TNBC, irradiation (IR) therapy is still a common treatment option for patients with lymph nodes or brain metastasis. Thus, it is urgent to develop strategies to enhance the sensitivity of TNBC tumors to low-dose IR. Here, the authors report that E3 ubiquitin ligase Ring finger protein 126 (RNF126) is important for IR-induced ATR-CHK1 pathway activation to enhance DNA damage repair (DDR). Mechanistically, RNF126 physically associates with the MRE11-RAD50-NBS1 (MRN) complex and ubiquitinates MRE11 at K339 and K480 to increase its DNA exonuclease activity, subsequent RPA binding, and ATR phosphorylation, promoting sustained DDR in a homologous recombination repair-prone manner. Accordingly, depletion of RNF126 leads to increased genomic instability and radiation sensitivity in both TNBC cells and mice. Furthermore, it is found that RNF126 expression is induced by IR activating the HER2-AKT-NF-κB pathway and targeting RNF126 expression with dihydroartemisinin significantly improves the sensitivity of TNBC tumors in the brain to IR treatment in vivo. Together, these results reveal that RNF126-mediated MRE11 ubiquitination is a critical regulator of the DDR, which provides a promising target for improving the sensitivity of TNBC to radiotherapy.

Substances (4)

Materials
Procduct Name CAS Molecular Formula Supplier Price
DHQHS 2 71939-50-9 C15H24O5 492 suppliers $5.00-$4500.00
DHQHS 2 71939-50-9 C15H24O5 492 suppliers $5.00-$4500.00
DHQHS 2 71939-50-9 C15H24O5 492 suppliers $5.00-$4500.00
DHQHS 2 71939-50-9 C15H24O5 492 suppliers $5.00-$4500.00

Similar articles

IF:4.6

Targeting cuproptosis by zinc pyrithione in triple-negative breast cancer.

iScience Xu Yang, Li Deng,etc Published: 16 October 2023
IF:10.5

Self-assembling mertansine prodrug improves tolerability and efficacy of chemotherapy against metastatic triple-negative breast cancer

Journal of Controlled Release Wei Ran , Xiaoyu Liu ,etc Published: 1 February 2020
IF:10

Hybrid Cell Membrane‐Coated Nanoparticles for Synergizing Sonodynamic Therapy and Immunotherapy against Triple‐Negative Breast Cancer

Advanced Healthcare Materials Jiali Gong, Danling Cheng,etc Published: 21 November 2024